BMY — BRISTOL MYERS SQUIBB CO

—
NYSE · Health Care · Pharmaceuticals · CIK 14272 ·
Last close
$61.35
Market Cap
$125.40B
52W High
$67.94
52W Low
$43.34
ADV30
11,381,959
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 13,069,000,000 8,923,000,000 4,401,000,000 2,162,000,000 88,772,000,000 9,574,000,000 65,368,000,000
Jun 2026 12,973,000,000 9,247,000,000 4,025,000,000 3,317,000,000 87,634,000,000 8,722,000,000 65,315,000,000
Mar 2026 11,489,000,000 8,068,000,000 3,365,000,000 2,677,000,000 86,476,000,000 9,574,000,000 66,374,000,000
Dec 2025 12,503,000,000 8,406,000,000 2,813,000,000 1,087,000,000 90,038,000,000 10,209,000,000 71,532,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$10,652,000,000
Investing CF
$-5,307,000,000
Financing CF
$-11,441,000,000
CapEx
$-1,366,000,000
Dividends Paid
$-5,119,000,000
Buybacks
—
EPS Diluted TTM
$4.51
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$21,190,000,000
Inventory
$2,704,000,000
Receivables
$12,851,000,000
ST Investments
$3,007,000,000
EBIT TTM
$12,985,000,000
Pretax Income TTM
$11,332,000,000
Interest Exp TTM
$1,653,000,000
Analysts
23

Yahoo Snapshot (yfinance, live)

Total Revenue
$50,033,999,872
EBITDA
$19,044,999,168
Free Cash Flow
$8,114,375,168
Enterprise Value
$161,614,807,040
Total Cash
$11,066,999,808
Total Debt
$45,053,001,728
Shares Out
2,044,085,831
Trailing EPS
$4.51
Book Value
$10.93
ROE
46.6%
ROA
10.7%
Div Yield
4.03%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 48,195,000,000 13,724,000,000 7,054,000,000 90,038,000,000 71,532,000,000 18,473,000,000 14,156,000,000
Dec 2024 48,300,000,000 5,887,000,000 -8,948,000,000 92,603,000,000 76,215,000,000 16,335,000,000 15,190,000,000
Dec 2023 45,006,000,000 8,195,000,000 8,025,000,000 95,159,000,000 65,674,000,000 29,430,000,000 13,860,000,000
Dec 2022 46,159,000,000 9,104,000,000 6,327,000,000 96,820,000,000 65,702,000,000 31,061,000,000 13,066,000,000

TTM Snapshot

Revenues TTM
$49,186,000,000
NetIncome TTM
$9,282,000,000
OpCashFlow TTM
—
Assets (Latest)
$87,634,000,000
Forward EPS
$6.63

Max Pain — expiry 2026-11-27

max pain strike: $62.00 · spot: $59.56 · call oi: 2,326 · put oi: 7,339
Expected Move to 2026-11-27: ±$2.80 (4.70%) — implied range $56.76 – $62.36 · ATM straddle on $60.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VRTX VERTEX PHARMACEUTICALS INC / MA $135.44B $534.20 —
NVO NOVO NORDISK A S $136.10B $40.70 —
SNY Sanofi $113.89B $47.53 —
GSK GSK plc $98.62B $49.24 —
REGN REGENERON PHARMACEUTICALS, INC. $97.34B $957.76 —

News headlines (Yahoo Finance, 1h cache)

Bristol-Myers Squibb: 3 Key Takeaways for Long-Term Investors
2026-11-18 20:20 · Yahoo
Missed Bristol-Myers Squibb's Rally? Here's What Early Buyers Saw
2026-11-18 17:11 · Yahoo
Altria or Bristol Myers Squibb: The One Dividend Stock I’d Hold for the Next 20 Years
2026-11-18 15:23 · Yahoo
Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
2026-11-18 14:10 · Yahoo
Bristol Myers Stock's Dividends Couldn't Close The Gap
2026-11-18 12:44 · Yahoo
Erasca Partners With Bristol Myers Squibb to Evaluate ERAS-0015 Combination Treatment for Pancreatic Cancer
2026-11-18 11:43 · Yahoo
Bristol Myers Squibb CEO says America’s edge in new drugs is ‘not a birthright’ as the U.S. loses its measles elimination status
2026-11-18 08:00 · Yahoo
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
2026-11-17 23:40 · Yahoo
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
2026-11-17 13:00 · Yahoo
Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?
2026-11-18 18:11 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.